OpenLB
Open Library of Bioscience
Advanced Search
Microbiology spectrum
Jan 11, 2024;12 (1): e0369223.

CRISPR-Cas9-mediated IncF plasmid curing in extraintestinal pathogenic .

Liang Chen, Gisele Peirano, Kelly Yen, Bingjie Wang, Austin Terlecky, Rebekah DeVinney, Barry N Kreiswirth, Johann D D Pitout
Author Information
  1. Liang Chen: Center for Discovery and Innovation, Hackensack-Meridian Health , Nutley, New Jersey, USA. ORCID
  2. Gisele Peirano: Cummings School of Medicine, University of Calgary , Calgary, Alberta, Canada.
  3. Kelly Yen: Center for Discovery and Innovation, Hackensack-Meridian Health , Nutley, New Jersey, USA.
  4. Bingjie Wang: Center for Discovery and Innovation, Hackensack-Meridian Health , Nutley, New Jersey, USA.
  5. Austin Terlecky: Center for Discovery and Innovation, Hackensack-Meridian Health , Nutley, New Jersey, USA.
  6. Rebekah DeVinney: Cummings School of Medicine, University of Calgary , Calgary, Alberta, Canada.
  7. Barry N Kreiswirth: Center for Discovery and Innovation, Hackensack-Meridian Health , Nutley, New Jersey, USA. ORCID
  8. Johann D D Pitout: Cummings School of Medicine, University of Calgary , Calgary, Alberta, Canada.
PMID: 38018989 DOI: 10.1128/spectrum.03692-23

Abstract

IMPORTANCE: Understanding the role of IncF plasmids in the success of drug-resistant bacteria has far-reaching implications for tackling antibiotic resistance. The study's use of a novel CRISPR-Cas9-mediated plasmid-curing system provides a precision tool for dissecting the specific impact of IncF plasmids on ExPEC clones, especially high-risk, multidrug-resistant strains like ST131, ST1193, and ST410. The study offers a crucial stepping stone for future research into understanding how these plasmids influence more complex aspects of bacterial behavior, such as cell invasion and fitness.

Keywords

CRISPR extraintestinal pathogenic Escherichia coli pCasCure plasmid

References

  1. Methods Mol Biol. 2010;642:113-21 [PMID: 20401590]
  2. Clin Microbiol Rev. 2019 Jun 12;32(3): [PMID: 31189557]
  3. Microbiol Mol Biol Rev. 2009 Dec;73(4):750-74 [PMID: 19946140]
  4. J Antimicrob Chemother. 2022 Nov 28;77(12):3399-3407 [PMID: 36204996]
  5. Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0051122 [PMID: 35658504]
  6. PLoS Comput Biol. 2017 Jun 8;13(6):e1005595 [PMID: 28594827]
  7. Eur J Clin Microbiol Infect Dis. 2021 Nov 9;: [PMID: 34750697]
  8. Appl Environ Microbiol. 2018 Nov 15;84(23): [PMID: 30217854]
  9. Antimicrob Agents Chemother. 2014 May;58(5):2871-7 [PMID: 24614371]
  10. Nature. 2010 Nov 4;468(7320):67-71 [PMID: 21048762]
  11. Emerg Infect Dis. 2020 Dec;26(12):2907-2915 [PMID: 33219650]
  12. Infect Dis Ther. 2023 Apr;12(4):1029-1041 [PMID: 36947392]
  13. EcoSal Plus. 2021 Feb;9(2): [PMID: 33634776]
  14. Antimicrob Agents Chemother. 2020 Aug 20;64(9): [PMID: 32631827]
  15. Emerg Infect Dis. 2022 May;28(5): [PMID: 35451367]
  16. Science. 2010 Jan 8;327(5962):167-70 [PMID: 20056882]
  17. Expert Rev Anti Infect Ther. 2023 Apr;21(4):343-353 [PMID: 36822840]
  18. J Antimicrob Chemother. 2018 May 1;73(5):1121-1137 [PMID: 29370371]

Grants

  1. R01 AI090155/NIAID NIH HHS

MeSH Term

Humans
Extraintestinal Pathogenic Escherichia coli
Escherichia coli Infections
CRISPR-Cas Systems
Plasmids
Anti-Bacterial Agents

Chemicals

Anti-Bacterial Agents
Journal Article
Article has an altmetric score of 2

Word Cloud

Created with Highcharts 10.0.0IncFplasmidsCRISPR-Cas9-mediatedplasmidextraintestinalpathogenicIMPORTANCE:Understandingrolesuccessdrug-resistantbacteriafar-reachingimplicationstacklingantibioticresistancestudy'susenovelplasmid-curingsystemprovidesprecisiontooldissectingspecificimpactExPECclonesespeciallyhigh-riskmultidrug-resistantstrainslikeST131ST1193ST410studyofferscrucialsteppingstonefutureresearchunderstandinginfluencecomplexaspectsbacterialbehaviorcellinvasionfitnesscuringCRISPREscherichiacolipCasCure

Similar Articles

Cited By